Showing results (171-180 of 192) with videos related to
Sort By:
Pageof 20
Science Translational Medicine|February 17, 2017
Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular diseaseMin Wei, Sebastian Brandhorst, Mahshid Shelehchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial CarcinomaSarmad Sadeghi, David Quinn, Tanya Dorff, et al.The Journal of Urology|August 6, 2013
Refining patient selection for neoadjuvant chemotherapy before radical cystectomyStephen H Culp, Rian J Dickstein, H Barton Grossman, et al.The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.Nature Communications|February 27, 2016
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancerNyam-Osor Chimge, Gillian H Little, Sanjeev K Baniwal, et al.Cancer|January 16, 2013
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance ProgramAnirban P Mitra, Jose E Castelao, Debra Hawes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialSteven G DuBois, Araz Marachelian, Elizabeth Fox, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.British Journal of Cancer|January 10, 2024
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trialMichael D Hogarty, David S Ziegler, Andrea Franson, et al.Pageof 20